8.3.4.1. Breast cancer
Restrictions:
Restricted to specialist initiation. Restricted to use on the advice of breast cancer specialists in accordance with regional protocols.
Restrictions:
Restricted to specialist initiation. Restricted to use on the advice of breast cancer specialists in accordance with regional protocols.
Restrictions:
Restricted to specialist use in accordance with regional protocol for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen.
Prescribing Notes:
The following indication is not recommended by SMC and remains non-Formulary:
- Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy
Restrictions:
For the management of advanced breast cancer (in pre- and peri- menopausal women), goserelin (but not Zoladex LA®) is approved where other treatments have failed.
Prescribing Notes:
For other indications, see sections 6.7.2 and 8.3.4.2
Restrictions:
Restricted to specialist initiation. Restricted to use on the advice of breast cancer specialists in accordance with regional protocols.
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Excludes tamoxifen liquid.
Restrictions:
Use in combination with tamoxifen or an aromatase inhibitor, for adjuvant treatment of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy is restricted to specialist initiation in accordance with regional protocol (in development).
Prescribing Notes:
For other indications for triptorelin, see sections 6.7.2 and 8.3.4.2